Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is 27.69% higher on its value in year-to-date trading and has touched a low of $176.36 and a high of $305.95 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VRTX stock was last observed hovering at around $286.94 in the last trading session, with the day’s loss setting it -6.54% off its average median price target of $310.50 for the next 12 months. It is also 27.92% off the consensus price target high of $389.00 offered by 28 analysts, but current levels are -12.16% lower than the price target low of $250.00 for the same period.
Currently trading at $280.40, the stock is -1.95% and -2.49% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.1 million and changing -2.28% at the moment leaves the stock 8.43% off its SMA200. VRTX registered 50.91% gain for a year compared to 6-month gain of 11.32%.
The stock witnessed a -4.57% loss in the last 1 month and extending the period to 3 months gives it a 2.97%, and is -1.57% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.37% over the week and 2.77% over the month.
Vertex Pharmaceuticals Incorporated (VRTX) has around 3900 employees, a market worth around $71.40B and $8.35B in sales. Current P/E ratio is 22.68 and Fwd P/E is 18.11. Profit margin for the company is 38.30%. Distance from 52-week low is 58.99% and -8.35% from its 52-week high. The company has generated returns on investments over the last 12 months (22.50%).
Vertex Pharmaceuticals Incorporated (VRTX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Vertex Pharmaceuticals Incorporated (VRTX) is a “Overweight”. 28 analysts offering their recommendations for the stock have an average rating of 2.10, where 10 rate it as a Hold and 3 think it is a “Overweight”. 15 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Vertex Pharmaceuticals Incorporated is expected to release its quarterly report on 11/02/2022.The EPS is expected to shrink by -12.50% this year
Vertex Pharmaceuticals Incorporated (VRTX) Top Institutional Holders
The shares outstanding are 255.90M, and float is at 255.88M with Short Float at 1.11%.
Vertex Pharmaceuticals Incorporated (VRTX) Insider Activity
A total of 194 insider transactions have happened at Vertex Pharmaceuticals Incorporated (VRTX) in the last six months, with sales accounting for 170 and purchases happening 24 times. The most recent transaction is an insider sale by Kewalramani Reshma, the company’s CEO & President. SEC filings show that Kewalramani Reshma sold 11,689 shares of the company’s common stock on Aug 15 at a price of $305.06 per share for a total of $3.57 million. Following the sale, the insider now owns 99598.0 shares.
Vertex Pharmaceuticals Incorporated disclosed in a document filed with the SEC on Aug 15 that Arbuckle Stuart A (EVP, COO) sold a total of 22,173 shares of the company’s common stock. The trade occurred on Aug 15 and was made at $303.93 per share for $6.74 million. Following the transaction, the insider now directly holds 45278.0 shares of the VRTX stock.
Still, SEC filings show that on Aug 15, Liu Joy (SVP, General Counsel) disposed off 3,747 shares at an average price of $303.90 for $1.14 million. The insider now directly holds 9,605 shares of Vertex Pharmaceuticals Incorporated (VRTX).
Vertex Pharmaceuticals Incorporated (VRTX): Who are the competitors?
The company’s main competitors (and peers) include AbbVie Inc. (ABBV) that is trading 30.95% up over the past 12 months and Krystal Biotech Inc. (KRYS) that is 23.19% higher over the same period. Arcturus Therapeutics Holdings Inc. (ARCT) is -72.17% down on the 1-year trading charts.